On ECHEMI
Home > Drugs > Chengdu Open Pharmaceutical Co., Ltd.
Chengdu Open Pharmaceutical Co., Ltd.
  • Founded in:

    2015-01-23
  • Country:

    China China
  • Address:

    No. 22, Yangheng 4th Road, Yang'an Industrial Park, Qionglai City
  • Tax NO.:

    91510183327478671X
  • Registered Funds:

    20 million yuan
  • Website:

  • Email:

Related Drugs
Ferrous Succinate Tablets
The main active ingredient of this product is ferrous succinate, which is an anhydrous alkaline salt containing 34.0% to 36.0% iron (Fe2).
Name Description Content CAS NO. Registered Holders
iron succinate

Iron is one of the important elements of the human body. It participates in the composition of hemoglobin and plays an important role in transferring oxygen and participating in human metabolic activities. Iron is the main component of hemoglobin and myoglobin. Hemoglobin is the main carrier of oxygen in red blood cells. Myoglobin is the site where muscle cells store oxygen and provides oxygen for muscle movement. Most enzymes and factors related to the tricarboxylic acid cycle contain iron, or can only function in the presence of iron. After actively supplementing iron for iron-deficient patients, in addition to accelerating hemoglobin synthesis, symptoms related to tissue iron deficiency and reduced iron-containing enzyme activity, such as growth retardation, abnormal behavior, lack of physical strength, changes in mucous tissues, and skin and nail lesions can also be gradually corrected.

More

Iron is one of the important elements of the human body. It participates in the composition of hemoglobin and plays an important role in transferring oxygen and participating in human metabolic activities. Iron is the main component of hemoglobin and myoglobin. Hemoglobin is the main carrier of oxygen in red blood cells. Myoglobin is the site where muscle cells store oxygen and provides oxygen for muscle movement. Most enzymes and factors related to the tricarboxylic acid cycle contain iron, or can only function in the presence of iron. After actively supplementing iron for iron-deficient patients, in addition to accelerating hemoglobin synthesis, symptoms related to tissue iron deficiency and reduced iron-containing enzyme activity, such as growth retardation, abnormal behavior, lack of physical strength, changes in mucous tissues, and skin and nail lesions can also be gradually corrected.

34.0%~36.0%Anhydrous basic salt 10030-90-7 10
Ferrous succinate
Name Description Content CAS NO. Registered Holders
iron succinate

Not clearly described

More

Not clearly described

10030-90-7 10
Sertraline Hydrochloride
Name Description Content CAS NO. Registered Holders
Sertraline hydrochloride

Extract from the above information

More

Extract from the above information

79559-97-0 52
Midodrine Hydrochloride Tablets
The main ingredient of this product is midodrine hydrochloride.
Name Description Content CAS NO. Registered Holders
Midodrine hydrochloride

The original form of this product is inactive. It is converted into the active metabolite desglymidodrine after aminoacetyl hydrolysis. Desglymidodrine is a selective peripheral sympathetic a1 receptor agonist, which acts directly on the postsynapse to release adrenaline stimulants. It has the function of regulating vascular tension, which can increase peripheral arterial and venous resistance, prevent a large amount of blood from accumulating in the lower limbs, promote blood return, keep blood volume stable, increase upright blood pressure, and improve symptoms caused by insufficient circulation volume. It will not cause increased excitability of the central nervous system and has no direct effect on the heart, but the heart rate may decrease due to feedback after taking the drug.

More

The original form of this product is inactive. It is converted into the active metabolite desglymidodrine after aminoacetyl hydrolysis. Desglymidodrine is a selective peripheral sympathetic a1 receptor agonist, which acts directly on the postsynapse to release adrenaline stimulants. It has the function of regulating vascular tension, which can increase peripheral arterial and venous resistance, prevent a large amount of blood from accumulating in the lower limbs, promote blood return, keep blood volume stable, increase upright blood pressure, and improve symptoms caused by insufficient circulation volume. It will not cause increased excitability of the central nervous system and has no direct effect on the heart, but the heart rate may decrease due to feedback after taking the drug.

3092-17-9 18
Cetirizine Hydrochloride
Name Description Content CAS NO. Registered Holders
Cetirizine dihydrochloride

Antihistamine effect

More

Antihistamine effect

83881-52-1 54
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.